$1.49 Billion is the total value of Rock Springs Capital Management LP's 133 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INSYQ | Exit | INSYS THERAPEUTICS INC NEW | $0 | – | -100,000 | -100.0% | -0.07% | – |
| CERN | Exit | CERNER CORP | $0 | – | -20,000 | -100.0% | -0.08% | – |
| AMSG | Exit | AMSURG CORP | $0 | – | -32,500 | -100.0% | -0.14% | – |
| MD | Exit | MEDNAX INC | $0 | – | -50,000 | -100.0% | -0.21% | – |
| BIOS | Exit | BIOSCRIP INC | $0 | – | -1,490,492 | -100.0% | -0.27% | – |
| GI | Exit | ENDOCHOICE HLDGS INC | $0 | – | -722,500 | -100.0% | -0.36% | – |
| EVHC | Exit | ENVISION HEALTHCARE HLDGS IN | $0 | – | -291,000 | -100.0% | -0.41% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -148,000 | -100.0% | -0.43% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -82,000 | -100.0% | -0.86% | – |
| HCA | Exit | HCA HOLDINGS INC | $0 | – | -430,000 | -100.0% | -2.04% | – |
| PFE | Exit | PFIZER INC | $0 | – | -1,055,800 | -100.0% | -2.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 43 | Q2 2024 | 4.0% |
| NEUROCRINE BIOSCIENCES INC | 42 | Q2 2024 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 42 | Q2 2024 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 42 | Q2 2024 | 2.4% |
| ACADIA HEALTHCARE COMPANY IN | 41 | Q2 2024 | 4.4% |
| ASCENDIS PHARMA A/S | 38 | Q2 2024 | 1.3% |
| BIOMARIN PHARMACEUTICAL INC | 38 | Q2 2024 | 1.3% |
| MACROGENICS INC | 38 | Q2 2024 | 0.5% |
| AMICUS THERAPEUTICS INC | 37 | Q2 2024 | 0.6% |
| ADAPTIMMUNE THERAPEUTICS PLC | 37 | Q2 2024 | 1.2% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Travere Therapeutics, Inc. | May 01, 2024 | 4,411,983 | 5.8% |
| Xilio Therapeutics, Inc. | April 05, 2024 | 3,003,259 | 8.7% |
| Aclaris Therapeutics, Inc. | February 14, 2024 | 2,998,495 | 4.2% |
| AGIOS PHARMACEUTICALS, INC. | February 14, 2024 | 2,152,173 | 3.8% |
| Gamida Cell Ltd.Sold out | February 14, 2024 | 0 | 0.0% |
| Immunocore Holdings plc | February 14, 2024 | 2,661,507 | 5.4% |
| Inozyme Pharma, Inc. | February 14, 2024 | 3,681,174 | 6.0% |
| Mereo BioPharma Group plc | February 14, 2024 | 39,919,255 | 5.7% |
| SPRUCE BIOSCIENCES, INC. | February 14, 2024 | 2,609,125 | 6.4% |
| Spyre Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.